Cognition Therapeutics (CGTX) Stock Price, News & Analysis

Company Overview

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease. In addition to its lead program, the company is advancing a preclinical pipeline aimed at expanding its approach to other neurodegenerative conditions. To support its global development efforts, Cognition Therapeutics collaborates with academic centers, contract research organizations and specialized clinical sites.

Headquartered in Pittsburgh, Pennsylvania, Cognition Therapeutics conducts operations primarily in the United States, with ongoing clinical and regulatory activities in European markets. The company is led by co-founder and CEO Stephen M. Maccecchini, Ph.D., who oversees research, development and strategic partnerships. Cognition Therapeutics’ common stock is traded on the NASDAQ under the ticker symbol CGTX.

Key Stats

• Today's Range: $0.89 to $0.94
• 50-Day Range: $0.89 to $1.68
• 52-Week Range: $0.55 to $3.83
• Volume: 403,630 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $79.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.33
• Consensus Rating: Moderate Buy

Cognition Therapeutics Stock Analysis - MarketRank™

Cognition Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 675th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cognition Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cognition Therapeutics has a consensus price target of $3.33, representing about 274.7% upside from its current price of $0.89.

Amount of Analyst Coverage

Cognition Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cognition Therapeutics are expected to grow in the coming year, from ($0.32) to ($0.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cognition Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cognition Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cognition Therapeutics has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.16% of the float of Cognition Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cognition Therapeutics has a short interest ratio ("days to cover") of 4.81.

Change versus previous month

Short interest in Cognition Therapeutics has recently increased by 36.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cognition Therapeutics does not currently pay a dividend.

Dividend Growth

Cognition Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.97

News Sentiment

Cognition Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cognition Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CGTX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cognition Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.11% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/01/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CGTX
• CIK: 1455365
• Web: www.cogrx.com
• Phone: 412-481-2210
• Fax: N/A
• Employees: 20
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Cognition Therapeutics: $3.33
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +274.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -72.68%
• Return on Assets: -53.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.92
• Quick Ratio: 5.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 89,500,000
• Free Float: 79,555,000
• Market Cap: $79.62 million
• Optionable: Not Optionable
• Beta: 1.75